Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OVR044
MIFTS: 35

Ovarian Carcinosarcoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Ovarian Carcinosarcoma

About this section

MalaCards integrated aliases for Ovarian Carcinosarcoma:

Name: Ovarian Carcinosarcoma 12 54 60 15 17
Ovarian Malignant Mixed Epithelial Mesenchymal Tumor 54 60
Malignant Mixed Müllerian Tumor of the Ovary 54 60
Ovarian Malignant Mixed Müllerian Tumor 54 60
Mmmt of the Ovary 54 60
Malignant Mixed Mullerian Tumor of the Ovary 54
Ovarian Malignant Mesodermal Mixed Tumor 12
Ovarian Malignant Mixed Mullerian Tumor 12
Carcinosarcoma of Ovary 74
Ovarian Mmmt 12

Characteristics:

Orphanet epidemiological data:

60
malignant mixed müllerian tumor of the ovary
Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 35
Orphanet: 60  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:6170
NCIt 51 C9192
ICD10 via Orphanet 35 C56
UMLS via Orphanet 75 C0392998
Orphanet 60 ORPHA213512
UMLS 74 C0392998
Sources

Summaries for Ovarian Carcinosarcoma

About this section
NIH Rare Diseases : 54 Ovarian carcinosarcoma, also known as a malignant mixed mullerian tumor (MMMT) of the ovary, is a rare, aggressive cancer of the ovary with characteristics of two types of cancer: carcinoma and sarcoma. Because women with this cancer often have no symptoms, more than half of women are diagnosed at an advanced stage. When present, symptoms may include pain in the abdomen or pelvic area, bloating or swelling of the abdomen, quickly feeling full when eating, or other digestive problems. The cause of ovarian carcinosarcoma is not yet understood. Treatment usually consists of surgery to remove the tumor and chemotherapy. The chance of recovery and long-term survival (prognosis) is poor, with a reported 5-year survival rate of about 28%.

MalaCards based summary : Ovarian Carcinosarcoma, also known as ovarian malignant mixed epithelial mesenchymal tumor, is related to carcinosarcoma and uterine corpus serous adenocarcinoma. An important gene associated with Ovarian Carcinosarcoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2). The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, liver and brain.

Disease Ontology : 12 A malignant ovarian surface epithelial-stromal neoplasm that is a mixed cell type cancer that has material basis in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components.

Sources

Related Diseases for Ovarian Carcinosarcoma

About this section

Diseases related to Ovarian Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
# Related Disease Score Top Affiliating Genes
1 carcinosarcoma 10.7
2 uterine corpus serous adenocarcinoma 10.2 ERBB2 TUBB3
3 breast cancer 10.2
4 inguinal hernia 10.2
5 bilateral breast cancer 10.2
6 uterine corpus cancer 10.1 ERBB2 TUBB3
7 stomach disease 10.1 ERBB2 TUBB3
8 paralytic squint 10.1 FUT2 TUBB3
9 female reproductive system disease 10.0 ERBB2 TUBB3
10 teratoma 10.0
11 reproductive system disease 10.0 ERBB2 TUBB3
12 gonadal disease 10.0 ERBB2 TUBB3
13 gastrointestinal system cancer 10.0 ERBB2 TUBB3
14 breast neuroendocrine neoplasm 10.0 ERBB2 SYP
15 mixed cell type cancer 9.9 ERBB2 SYP
16 granulosa cell tumor of the ovary 9.9 ERBB2 SYP
17 olfactory nerve neoplasm 9.9 SYP TUBB3
18 tubular adenocarcinoma 9.9 ERBB2 SYP
19 pineal gland cancer 9.9 SYP TUBB3
20 pineocytoma 9.9 SYP TUBB3
21 cranial nerve malignant neoplasm 9.9 SYP TUBB3
22 sweat gland cancer 9.9 ERBB2 SYP
23 myeloma, multiple 9.9
24 tubulin, beta 9.9
25 angiosarcoma 9.9
26 melanoma 9.9
27 cystic teratoma 9.9
28 cystadenocarcinoma 9.9
29 serous cystadenocarcinoma 9.9
30 rhabdomyosarcoma 9.9
31 liposarcoma 9.9
32 mature teratoma 9.9
33 pleomorphic liposarcoma 9.9
34 cerebellar degeneration 9.9
35 paraneoplastic cerebellar degeneration 9.9
36 pineal parenchymal tumor of intermediate differentiation 9.9 SYP TUBB3
37 respiratory system disease 9.9 CD274 TUBB3
38 adult medulloblastoma 9.9 SYP TUBB3
39 respiratory system cancer 9.9 CD274 ERBB2 TUBB3
40 central nervous system cancer 9.9 SYP TUBB3
41 nervous system cancer 9.9 SYP TUBB3
42 merkel cell carcinoma 9.8 CD274 SYP
43 thymus cancer 9.8 CD274 SYP
44 endocrine gland cancer 9.7 ERBB2 SYP TUBB3
45 nervous system disease 9.5 SYP TUBB3
46 lung cancer 9.1 CD274 ERBB2 SYP TUBB3

Graphical network of the top 20 diseases related to Ovarian Carcinosarcoma:



Diseases related to Ovarian Carcinosarcoma
Sources

Symptoms & Phenotypes for Ovarian Carcinosarcoma

About this section
Sources

Drugs & Therapeutics for Ovarian Carcinosarcoma

About this section

Drugs for Ovarian Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
3
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
4
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
5
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 1 23214-92-8 31703
6
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
7
Ifosfamide Approved Phase 3 3778-73-2 3690
8
Niraparib Approved, Investigational Phase 2, Phase 3 1038915-60-4 24958200
9
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
10
Histamine Approved, Investigational Phase 3 51-45-6 774
11
Cyproheptadine Approved Phase 3 129-03-3 2913
12
Doxil Approved June 1999 Phase 2, Phase 3,Phase 1 31703
13 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
14 Antimitotic Agents Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
16 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
17 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
18 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
19 Alkylating Agents Phase 3,Phase 2
20 Antineoplastic Agents, Alkylating Phase 3,Phase 2
21
Isophosphamide mustard Phase 3 0
22 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1
23 Gastrointestinal Agents Phase 3
24 Histamine Antagonists Phase 3
25 Antipruritics Phase 3
26 Dermatologic Agents Phase 3
27 Anti-Allergic Agents Phase 3
28
Histamine Phosphate Phase 3 51-74-1 65513
29 Neurotransmitter Agents Phase 3
30 Histamine H1 Antagonists Phase 3
31 Serotonin Agents Phase 3
32 Serotonin Antagonists Phase 3
33
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
34
Cisplatin Approved Phase 2,Phase 1 15663-27-1 441203 84093 2767
35
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
36
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
37
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
38
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751
39
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
40
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
41
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
42
MK-1775 Investigational Phase 2 501-36-0, 955365-80-7 24856436 445154
43 Immunosuppressive Agents Phase 2
44 Antimetabolites Phase 2
45 Anti-Infective Agents Phase 2
46 Antiviral Agents Phase 2
47 Antimetabolites, Antineoplastic Phase 2
48 Immunologic Factors Phase 2,Phase 1
49 Anti-Bacterial Agents Phase 2,Phase 1
50 Antibiotics, Antitubercular Phase 2,Phase 1

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
2 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
3 Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib Not yet recruiting NCT03651206 Phase 2, Phase 3 Niraparib;Chemotherapy Drugs
4 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
5 Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Unknown status NCT00838656 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
6 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
7 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
8 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
9 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
10 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
11 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
12 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
13 Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
14 Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma Recruiting NCT03610490 Phase 2 Cyclophosphamide;Fludarabine
15 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
16 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2 Trabectedin
17 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
18 Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Completed NCT00352300 Phase 1 Carboplatin;Paclitaxel
19 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
20 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
21 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Recruiting NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
22 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
23 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Completed NCT01080521
24 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors Recruiting NCT03641287 Not Applicable
25 Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial Terminated NCT00904514

Search NIH Clinical Center for Ovarian Carcinosarcoma

Sources

Genetic Tests for Ovarian Carcinosarcoma

About this section
Sources

Anatomical Context for Ovarian Carcinosarcoma

About this section

MalaCards organs/tissues related to Ovarian Carcinosarcoma:

42
Ovary, Liver, Brain, Endothelial, Lymph Node, Small Intestine
Sources

Publications for Ovarian Carcinosarcoma

About this section

Articles related to Ovarian Carcinosarcoma:

(show all 47)
# Title Authors Year
1
Ovarian carcinosarcoma: Current developments and future perspectives. ( 30771873 )
2019
2
Ovarian Carcinosarcoma and Concurrent Serous Tubal Intraepithelial Carcinoma With Next-Generation Sequencing Suggesting an Origin From the Fallopian Tube. ( 30913944 )
2019
3
Usefulness of ascites cytology for the evaluation of chemotherapy response in ovarian carcinosarcoma. ( 29488261 )
2018
4
Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature. ( 29426293 )
2018
5
Prognostic significance of lymph node metastasis and lymphadenectomy in early-stage ovarian carcinosarcoma. ( 30022854 )
2018
6
Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma. ( 30147940 )
2018
7
Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis. ( 30345126 )
2018
8
Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma. ( 28791266 )
2017
9
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. ( 28679774 )
2017
10
Paraneoplastic cerebellar degeneration secondary to ovarian carcinosarcoma: a cerebellar conundrum. ( 28790096 )
2017
11
Clinical Significance of Programmed Death Liganda891 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. ( 28125702 )
2017
12
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. ( 27958685 )
2017
13
Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis. ( 27107722 )
2016
14
Ovarian Carcinosarcoma and Its Association with Mature Cystic Teratoma and Primary Tubal Carcinoma. ( 27807494 )
2016
15
Mature Teratoma Associated with Bilateral Ovarian Carcinosarcoma - Accidental Association or Etiopathogenetic Determinism? - Case Report. ( 27819640 )
2016
16
Presence of both Mesenchymal and Carcinomatous Features in an In-vitro Model of Ovarian Carcinosarcoma Derived from Patients' Ascitic Fluid. ( 25802693 )
2015
17
Ovarian carcinosarcoma: a case report, diagnosis, treatment and literature review. ( 27418786 )
2015
18
Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. ( 25962155 )
2015
19
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTEAr), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. ( 26474755 )
2015
20
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma. ( 25341582 )
2014
21
A rare case of ovarian carcinosarcoma with neuroendocrine differentiation. ( 24971408 )
2014
22
Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma. ( 24631447 )
2014
23
Ovarian carcinosarcoma in a renal transplant recipient. A unique case of a rare tumor. ( 26052208 )
2014
24
Rhabdomyosarcoma with pseudolipoblasts arising in ovarian carcinosarcoma: a distinctive postchemotherapy morphologic variant mimicking pleomorphic liposarcoma. ( 24587930 )
2014
25
Ovarian carcinosarcoma associated with bilateral tubal intraepithelial carcinoma: a case report. ( 23722511 )
2013
26
Large polyp of the small intestine: an unexpected metastasis of ovarian carcinosarcoma. ( 23926191 )
2013
27
Prognostic determinants in patients with uterine and ovarian carcinosarcoma. ( 23947079 )
2013
28
Ovarian carcinosarcoma: effects of cytoreductive status and platinum-based chemotherapy on survival. ( 23781249 )
2013
29
Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. ( 23450567 )
2013
30
Complete response with pegylated liposomal doxorubicin as a second-line therapy in metastatic ovarian carcinosarcoma: Significance of assessment of the response by FDG-PET. ( 24371621 )
2012
31
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. ( 22209775 )
2012
32
A rare case of ovarian carcinosarcoma successfully treated with the neoadjuvant chemotherapy of paclitaxel and ifosfamide. ( 21417665 )
2011
33
Solitary splenic metastasis from ovarian carcinosarcoma: a case report. ( 21310035 )
2011
34
Malignant melanoma arising in an ovarian carcinosarcoma: case report and review of the literature. ( 21293284 )
2011
35
Whole-body FDG PET/CT in diagnosis of internal mammary nodal metastasis of ovarian carcinosarcoma. ( 21552025 )
2011
36
Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma. ( 19820383 )
2009
37
Current management of ovarian carcinosarcoma. ( 17362309 )
2007
38
Clinical features and outcomes of uterine and ovarian carcinosarcoma. ( 16271748 )
2006
39
Complete cytoreduction combined with early postoperative intraperitoneal chemotherapy for ovarian carcinosarcoma. Report of two cases. ( 16645301 )
2006
40
A case of primary ovarian carcinosarcoma and vulvar carcinoma with widespread lymphadenopathy. ( 16846899 )
2006
41
Primary ovarian carcinosarcoma: a case report and review of the literature. ( 15493190 )
2004
42
Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. ( 12893202 )
2003
43
Unusual Trousseau's syndrome in ovarian carcinosarcoma: multiple systemic thromboembolic events. ( 12554280 )
2002
44
Borderline serous cystadenocarcinoma with coexistent angiosarcoma: an unusual form of ovarian carcinosarcoma. ( 12574850 )
2001
45
Ovarian carcinosarcoma [correction of carcinoma]. ( 11418412 )
2001
46
Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases. ( 11119124 )
2000
47
MR images of ovarian carcinosarcoma. ( 10646984 )
1999
Sources

Variations for Ovarian Carcinosarcoma

About this section
Sources

Expression for Ovarian Carcinosarcoma

About this section
Search GEO for disease gene expression data for Ovarian Carcinosarcoma.
Sources

Pathways for Ovarian Carcinosarcoma

About this section
Sources

GO Terms for Ovarian Carcinosarcoma

About this section
Sources

Sources for Ovarian Carcinosarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....